OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
A landscape analysis and discussion of value of gene therapies for sickle cell disease	27
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	20
Adherence to augmentation therapy for the treatment of major depressive disorder	20
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	20
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden	15
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	14
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	13
The hidden burden of atopic dermatitis in central and Eastern European countries	13
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	13
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	13
The cost-of-illness of multiple sclerosis in Jordan	13
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	12
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	11
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	11
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	10
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	10
Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs	10
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	9
How to create value with constrained budgets in oncological care? A narrative review	9
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	9
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	8
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	8
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis	8
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	8
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	8

Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations	8
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	8
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	8
How unprofessional behaviours between healthcare staff threaten patient care and safety	8
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	7
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?	7
Indication-based pricing of the pharmaceuticals in Croatia: case-study	7
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	7
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review	7
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review	6
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	6
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency	6
What to expect in 2024: important health economics and outcomes research (HEOR) trends	6
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System	6
Economic benefits of global Collaborative Health technology	6
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	6
Nonadherence to antiseizure medications: what have we learned and what can be done next?	6
Assessing the economic impact of digital endpoints on medication adherence	6
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	5
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	5
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	5
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	5
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	5
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	5
Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer’s disease and related dementias	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review	5
Cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing device for treatment of heavy menstrual bleeding: a systematic review	5
Social care data in the UK; current landscape, challenges, and future recommendations	5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	4
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	4
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A	4
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	4
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	4
The utility and impact of digital endpoints for improving breast cancer outcomes	4
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	4
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand	4
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	4
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	4
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	4
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	4
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	4
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	4

Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	4
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension	4
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	4
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	4
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms	4
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	4
Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review	4
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	4
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	4
Natural language processing – relevance to patient outcomes and real-world evidence	4
An early cost analysis of magnetic bone growth stimulation in England	4
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Measuring valued output in primary care: challenges and reconciliation	3
Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US	3
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	3
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia	3
Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Psychometric properties of the Polish version of SF-12v2 in the general population survey	3
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	3
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	3
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	3
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	3
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	3
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review	3
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	3
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	3
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis	3
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer	3
Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control	3
Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?	3
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	3
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	3
Evaluation instruments for executive functions in children and adolescents: a systematic review	3
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	3
Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals	3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach	3
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	3
Consumption of antidepressants and economic austerity in Brazil	3
Health-related quality of life measured using the EQ-5D-3L: iranian population norms	3
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	3